Insight Molecular Diagnostics Inc. — Director's Dealing 2023

Jun 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2023-06-23

Reporting Person: Last Andrew J. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-23	Common Stock, no par value	A	20000	—	Acquired	90170	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-23	Option to Purchase Common Stock	$0.20	A	90000	Acquired	2033-06-23	Common Stock (90000)	Direct

Footnotes

F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F2: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.